Hematologist/Medical Oncologist

Sonia Benn, MD

Specialty Area
Medical Oncology
Locations
Desoto
7668 Airways Boulevard
Southaven MS 38671 662.349.9556
West Cancer Center welcomed Sonia M. Benn, MD, a Hematology/Oncology specialist, to their team in February 2006. Dr. Benn is honored to be a part of the West Cancer Center team and is passionate about providing care to her patients that transcends the clinical to include the whole person – physically, emotionally, and socially. Dr. Benn treats patients at the Desoto office located in Southaven, MS, and plays a vital role in the healthcare community. Originally from Trinidad, West Indies, Dr. Benn grew up in Huntsville, AL. She is married to Lester, a local architect. In her leisure time, she enjoys cooking, playing the violin and piano and spending time with her husband and children.

Undergraduate:

 

Medical School:

University Of Tennessee Health Science Center College Of Medicine in Memphis

Residency:

University Of Tennessee Health Science Center College Of Medicine in Memphis

 

Fellowship:

Johns Hopkins University/Sinai Hospital in Baltimore, MD
Winner of Best Oncologist, Desoto Times Tribune, 2012 & 2014
Medical Oncologist and Hematologist, West Cancer Center Assistant Affiliated Professor of Medicine, University of Tennessee Health Science Center, Memphis, TN Board member, Community Oncology Alliance, 2010-2011
Areas of Expertise Breast Cancer Gastrointestinal Cancer Research Dr. Benn’s research focused on “A Multicenter, Open-Label, Single Arm, Phase II Trial Investigating the Efficacy and Tolerability of Vinorelbine, Carboplatin and Trastuzumab for the First-Line Treatment of Metastatic Breast Cancer in Women with Her2+ Disease”. Dr. Benn examined the relationship of dehydroepiandrosterone (DHEA) and its sulfated ester with cardiovascular risk factors as a resident of The University of TN. Dr. Benn is currently involved in the clinical trials in Hematology and Oncology conducted by West Cancer Center.
Dr. Benn’s recent publication discussed adjuvant trastuzumab (T) therapy in HER2 + breast cancer after ASCO 2005 in relation to patients’ attitudes and immediate economic burden.